Ulti_1170x120_5-11-20

Dr. Reddy’s

Dr. Reddy’s introduces ziprasidone mesylate for injection

Dr. Reddy’s introduces ziprasidone mesylate for injection

PRINCETON, N.J. — Dr. Reddy’s  has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration. “We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from

Dr. Reddy’s launches trientine hydrochloride capsules

Dr. Reddy’s launches trientine hydrochloride capsules

PRINCETON, N.J. — Dr. Reddy’s announced the launch of trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration. “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head

Dr. Reddy’s launches O-T-C, store-brand equivalent of Prevacid 24HR capsules

Dr. Reddy’s launches O-T-C, store-brand equivalent of Prevacid 24HR capsules

PRINCETON, N.J. — Dr. Reddy’s announced Monday the launch of lansoprazole delayed-release capsules USP, 15 mg, an over-the-counter (O-T-C) store-brand equivalent of Prevacid 24HR capsules, in the United States market, as approved by the U.S. Food and Drug Administration. Dr. Reddy’s O-T-C lansoprazole delayed-release capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI)

Amneal among companies to launch generic version of Lyrica

Amneal among companies to launch generic version of Lyrica

BRIDGEWATER, N.J.  — The Food and Drug Administration has approved a number of applications for the generic version of Pfizer’s Lyrica (pregabalin). The  FDA gave the green light to the following companies: Amneal, Alembic, Alkem, Dr. Reddy’s, InvaGen, MSN Laboratories, Rising Pharmaceuticals, Sciegen, and Teva. Amneal’s  generic version of Lyrica (pregabalin capsules) will be available

Dr. Reddy’s intros generic O-T-C version of Allegra-D

Dr. Reddy’s intros generic O-T-C version of Allegra-D

PRINCETON, N.J. — Dr. Reddy’s Laboratories has introduced an over-the-counter store-brand equivalent of Chattem’s Allegra-D (fexofenadine 60 mg and pseudoephedrine 120 mg) extended-release tablets. This is an O-T-C store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).  “We

Dr. Reddy’s releases O-T-C store brand equivalent of Mucinex D extended release tablets

Dr. Reddy’s releases O-T-C store brand equivalent of Mucinex D extended release tablets

PRINCETON, N.J. — Dr. Reddy’s announced launch of an over-the-counter (O-T-C) store-brand equivalent of Mucinex D Extended Release Tablets in two strengths— guaifenesin 600 mg and pseudoephedrine HCl 60 mg, and guaifenesin 1200 mg and pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

Dr. Reddy’s announces the re-launch of its buprenorphine and naloxone sublingual film

PRINCETON, N.J.— Dr. Reddy’s Laboratories announced this week the re-launch of its buprenorphine and naloxone sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The re-launch comes on the heels of a favorable

Dr. Reddy’s to acquire ANDAs from Teva, Allergan

Dr. Reddy’s to acquire ANDAs from Teva, Allergan

HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories plans to buy eight Abbreviated New Drug Applications (ANDAs) in the United States from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc for $350 million in cash. Dr. Reddy’s, which announced the agreement over the weekend, said the acquired products are being divested by